Mirum Pharmaceuticals Inc. (MIRM)
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MIRM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.28B
- Forward P/E
- 300.41
- EPS (TTM)
- -$14.47
- Dividend yield
- None
- 52-week range
- 63.23 – 130.00
- Day range
- 94.10 – 98.39
- Volume / Avg
- 1.06M / 692.51K
- Beta
- —
- Shares outstanding
- 65.28M
52-week range
MIRM stock today
Mirum Pharmaceuticals (MIRM) closed at $96.13 on Nov 20, up 0.65% (+$0.62), versus the S&P 500's 3.70% decline. Shares are 26.1% below their 52-week high of $130.00, set on Jul 9, 2026 and 52.0% above the 52-week low of $63.23, in the middle of the past year's range. MIRM is up 21.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.5%.
Mirum Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$14.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mirum Pharmaceuticals
Company profileMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Christopher Peetz
- Headquarters
- Foster City, CA
- Employees
- 470
- IPO year
- 2019
- Website
- mirumpharma.com
Financial highlights
Full financialsIn fiscal 2025, Mirum Pharmaceuticals generated $521.3 million in revenue, up 54.7% from fiscal 2024, its 5th consecutive year of revenue growth. Mirum Pharmaceuticals reported a net loss of $23.4 million, compared with a loss of $87.9 million a year earlier. Operating margin was -4.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M |
| Growth | +54.74% | +80.76% | +141.85% | +302.66% | — |
| Net income | $-23.36M | $-87.94M | $-163.41M | $-135.66M | $-83.99M |
| EPS (diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$157.71+64.06%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.87 vs $-0.53
- Surprise
- -64.15%
MIRM news
All MIRM news- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike DealsNasdaqAMGN, ARGX, AZN, BEAM
- Mirum Pharmaceuticals' Brelovitug Meets Primary Endpoint In Phase 3 AZURE-4 StudyNasdaqMIRM, ET
- Mirum Pharmaceuticals Reports Q3 2026 Financial Results and Raises Full-Year Sales GuidanceNasdaq
- Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire
- Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026Business Wire
- FDA Drug Approvals In September 2026NasdaqABBV, AZN, INCY, IONS
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report DataNasdaqABBV, ANL, ARWR, AZN
- Mirum Pharmaceuticals to report Livmarli trial results MondaySeeking Alpha
Mirum Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs MIRM |
| SUPNSupernus Inc. | 28.61 | +0.92% | $5.94B | vs MIRM |
| ARWRArrowhead Pharmaceuticals Inc. | 41.37 | -5.22% | $5.85B | vs MIRM |
| LGNDLigand Pharmaceuticals Incorporated | 286.85 | -0.03% | $5.74B | vs MIRM |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs MIRM |
| GRFSGrifols S.A. ADR | 8.15 | -0.61% | $5.55B | vs MIRM |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs MIRM |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs MIRM |
Indexes, lists and sector
Mirum Pharmaceuticals stock FAQ
What is Mirum Pharmaceuticals's stock price today?
MIRM last traded at $96.13 as of Nov 20, 4:00 PM EST, up 0.65% on the day. Prices are delayed at least 15 minutes.
Who is Mirum Pharmaceuticals's CEO?
Mr. Christopher Peetz is the chief executive officer of Mirum Pharmaceuticals Inc., which has about 470 employees.
What is the MIRM 52-week high?
The 52-week high for MIRM is $130.00 and the 52-week low is $63.23. The stock is currently 26.1% below its high.